Elevated serum levels of the aminoterminal propeptide of type 1 procollagen (P1NP) are associated with a poor prognosis in metastatic prostate cancer MK Enver, U Otite, R Iles, FI Chinegwundoh, R Persad and V Nargund Departments of Urology and Molecular Biology, St Bartholomew's Hospital, London, UK Introduction Serum P1NP is useful in identifying prostate cancer patients with bone metastases. It is released from bone by osteoblastic bone metastasis activity. This study aims to determine the value of P1NP as a prognostic indicator in prostate cancer patients with bone metastases. Methods A radioimmunoassay kit was used to determine serum P1NP levels in 18 newly diagnosed prostate cancer patients with bone metastases confirmed on bone scan. All patients were treated by LHRH agonists, and followed up for a median of 27 months. Serum P1NP levels were classified as high (> 90 mg/l) or low (< 90 mg/l). Age, PSA and Gleason score did not significantly differ in the two groups.
Introduction
Serum P1NP is useful in identifying prostate cancer patients with bone metastases. It is released from bone by osteoblastic bone metastasis activity. This study aims to determine the value of P1NP as a prognostic indicator in prostate cancer patients with bone metastases. Methods A radioimmunoassay kit was used to determine serum P1NP levels in 18 newly diagnosed prostate cancer patients with bone metastases confirmed on bone scan. All patients were treated by LHRH agonists, and followed up for a median of 27 months. Serum P1NP levels were classified as high (> 90 mg/l) or low (< 90 mg/l). Age, PSA and Gleason score did not significantly differ in the two groups.
Results
Patients with high P1NP levels (n ¼ 9) were found to have a mean survival time of 28.3 months (95% CI 21.8 -34.8), whereas those with low levels (n ¼ 9) had a mean survival time of 13.6 months (95% CI 6.7 -20.4). This difference in survival time was significant (P < 0.05). Conclusions Measurement of serum P1NP levels in newly diagnosed prostate cancer patients with bone metastases may be a simple way of identifying those with poorer prognosis.
Introduction
Oxidative stress is recognized to contribute to the nutritional decline of cancer patients. 1 The basis of this oxidative stress could either be due to the tumour itself or a host response. The oxidative damage caused by free radical activity to lipoproteins can be assessed in the circulation since it results in the formation of lipid peroxide products such as malondialdehyde (MDA). The aim of this study was to examine the relationship between stage of disease, host response (inflammatory response, C-reactive protein) and oxidative stress (MDA) in patients treated for prostate cancer. Methods Patients with BPH (n ¼ 18), localized (n ¼ 14) and metastatic (n ¼ 32) prostate cancer were studied. Fasting blood samples were removed for the measurement of PSA, CRP MDA and cholesterol. MDA concentrations were adjusted for cholesterol. Results Compared with BPH the hormone responsive cancer patients irrespective of stage had similar PSA concentrations. In contrast, patients with metastatic disease had higher CRP (P ¼ 0.022) and MDA (0.042) concentrations compared with localized disease. In the prostate cancer patients CRP was not correlated with adjusted MDA concentrations.
Conclusions
In patients treated for prostate cancer oxidative stress is associated with the stage of disease but does not appear to be associated with the magnitude of the systemic inflammatory response. Epidemiological and migration studies suggest that environmental factors have a strong influence on etiogenesis of prostate cancer. The WHO has listed dietary fat and red meat consumption as risk factors for prostate cancer. A variety of mutagens present in cooked meat were tested for carcinogenic potential in this study. Methods Five histologically benign prostate samples were used for this study. Four samples were incubated with the environmental carcinogens PhIP [2-amino1-methyl6-phenyl imidazo pyridine], IQ [2-amino3-methyl imidazo quinoline] and one sample with B(a)P [benzo(a) pyrene]. The DNA extracted from each tissue was postlabelled with P 32 and the DNA adducts were quantified by semi-quantitative analysis in comparison with a standard activity curve. Total RNA was extracted from a fresh frozen prostate sample and analysed using micro-array technique in comparison with muscle RNA. Results P 32 postlabelling showed that all tissues showed evidence of DNA adduct formation with the carcinogens. Adducts for IQ ranged from 48 to 461 adducts/10 10 nucleotides. PhIP adducts ranged from 9 to 23 adducts/ 10 10 nucleotides. B(a)P adducts ranged from 57 to 180 adducts/10 10 nucleotides. Micro-array analysis showed eight genes coding for metabolic enzymes were differentially expressed by a factor of 3. These included key xeno-biotic metabolizing enzymes (CYP IIE1, GST theta1, CYP reductase, CY C oxidase subunit VIIb and MAO B). 
Discussion
The polycyclic aromatic hydrocarbons and the heterocyclic amines incubated with the prostate need to be biologically activated before they can cause covalent bonding to the guanine bases of the DNA to form adducts. This involves N-hydroxylation by cytochrome p450 enzymes and this N-hydroxy derivatives are further o-esterified catalysed by N-acetyl transferases/sulphotransferases to form reactive nitrenium ion derivatives. These covalently bind with DNA to form adducts. Demonstration of overexpression of the key xenobiotic enzymes by microarrays and DNA adducts in prostate tissue by P 32 postlabelling confirms that prostate necessarily expresses at least one of the alleles of CYP and NAT/ SULT enzymes to metabolize these cooked meat carcinogens to form DNA adducts. Conclusion Overexpression of key xenobiotic enzymes and the presence of DNA adducts in benign prostate tissue confirms human prostate can metabolically activate 'cooked meat' carcinogens, which can contribute to the development of prostate cancer.
Introduction
Hormonal therapy remains the treatment of choice for metastatic prostate cancer. However development of androgen escape is a serious clinical problem, for which there is currently no effective therapy. AP-1 is a complex of transcription factors c-Jun and c-fos, activated by protein kinase C. These proteins are up-regulated in prostate cancer cell lines in the absence of androgens and there is a strong evidence that PKC activity is required for the survival and growth of androgen independent human prostate cancer cells. In-vivo studies are yet to be carried out. We propose to investigate this using human prostate cancer tissue. Aims 1. To investigate the levels of expression of c-Jun, c-fos and AR protein levels in paired pre-and post-cancer tissue from prostate cancer patients who have developed androgen escape. 2. To identify patients in whose tumours up-regulation of AP-1 may be mediating androgen escape. Methods Forty-one patients with prostate cancer who had progressed to androgen escape were identified retrospectively from their clinical records. Their pre-and postandrogen escape prostate tumour tissue (41 paired samples) provided material for study. Phosphorylated c-jun, c-fos, AR and PSA levels of expression were quantified by immunohistochemistry. Results PSA was expressed in all the tissue samples tested indicating activation of androgen-regulated genes. Increased expression of c-Jun/c-fos was observed in 32% (13/41) of post-androgen escape samples when compared with preandrogen escape values. AR expression remained unaltered or decreased in 56% (23/41) of post-androgen escape prostate cancer biopsies when compared to the matched pre-androgen escape tissue. AR expression was increased in 44%. No significant difference in c-jun/fos expression was observed in tumours with increased AR vs no change in AR expression.
Conclusion
We have demonstrated up-regulation and activation (via phosphorylation of c-jun) of the AP-1 transcription factor in a significant subset (32%) of patients who have progressed to androgen escape, independent of changes in AR expression. In this subset of patients, AP-1 may have a dominant effect in cancer progression via activation of androgen regulated genes by an AR-independent mechanism. This study suggests that the AP-1 could be a potential target for future therapies against androgen escape in a selected group of patients.
Introduction
Cell cycle progression is controlled by a family of cyclindependent kinases (CDK), which are regulated by CDK inhibitors such as p21 WAF1 . DNA damage and STAT1 (signal transduction and activators of transcription) may induce p21 WAF1 expression. This leads to cell cycle arrest/ apoptosis at the G1 check-point, via or independently of p53. Consequently p21 WAF1 may act as a tumour suppressor gene (TSG) and loss of the p21 WAF1 gene has been reported in cancer. Hypermethylation of the promoter region is one of the commonest mechanisms for TSG inactivation found in cancer. The aim of this study was to see whether p21 WAF1 is inactivated in prostate cancer cell lines and to examine the methylation status of the promoter region. Method PC3, LNCaP and DU145 prostate cancer cell lines were cultured in a 2 mM solution of 5-Aza-2 deoxycytidine (5AzaCdR) for one week, in parallel with untreated cells. 5AzaCdR sequesters the enzyme DNA methyltransferase and thus prevents DNA methylation. mRNA was extracted (Qiagen RNeasy kit) from the treated and untreated cell lines and RT-PCR performed. DNA from the untreated cell lines was extracted (Qiagen DNeasy kit) and treated with sodium bisulphite. This converts cytosine nucleotides to thymidine unless a methyl group protects the cytosine. PCR and sequencing of the promoter was performed. Results RT-PCR demonstrated p21 WAF1 is inactivateded in prostate cancer cell lines but is reactivated by treatment with 5AzaCdR. Sequence analysis of part of the promoter region revealed several sites of methylation at the 5 0 end of a CpG island in the PC3, LNCaP and DU145 cell line DNA but not in the no cancer control DNA. Most notably the Sis-inducible element (SEI)-1, a STAT1 binding site, was methylated.
Conclusions
In bowel, gastric, bladder and non-small cell lung cancers lack of expression of p21 WAF1 is related to poor prognosis. In this study we show that p21 WAF1 is not expressed in metastatic prostate cancer cell lines. Furthermore, several cytosine residues in the promoter region are methylated, in particular the SIE-1 site where STAT1 binding occurs. The inhibition of the STAT1 signalling pathway by methylation may inactivate the p21 WAF1 tumour suppressor gene in prostate cancer.
Introduction
ERK5 is required for EGF-induced cellular proliferation and progression through the cell cycle. 1 We have recently shown that MEK5, the specific activator of ERK5, is overexpressed in prostate cancer and is associated with metastatic disease and poor survival. ERK5 has three splice variants, namely a, b, and c, encoding for different amino termini. 2 The full length ERK5a is catalytically active, whereas the b and c forms are dominant negative kinases. We studied the expression of ERK5 isoforms, to further characterize the function of the MEK5/ERK5 pathway in human prostate cancer. Materials and methods Primers flanking the region in which ERK5 varies in the three splice isoforms were designed. RNA was extracted from a panel of human prostate, bladder, breast and colon cancer cell lines. It was then subjected to reverse transcription PCR analysis. Snap frozen resected prostatic (seven BPH, nine cancer) tissue were also studied. Western blotting was performed on four of the cell lines to confirm ERK5 expression.
Results
The amplicons seen were related to the presence and size of the intron insert at the region of interest: a, 115 bp; b, 175 bp; c, 251 bp. In J82 bladder cancer cells, all three ERK5 isoforms were detected with the 'a' and 'c' forms predominant. In the other of the cell lines examined, only ERK5 'a' variant was detected. Uniform ERK5 'a' expression was also seen in the benign and malignant prostate tissue throughout all the samples. Western blotting of the cell lines exhibited the same expression pattern as was seen in the PCR results. Discussion and conclusion In murine tissue all three ERK5 isoforms are expressed in testis, brain, kidney, lung and heart. The expression of the 'a' and 'c' forms are much stronger than the 'b' form. We have shown that ERK5 'a' is expressed in human prostatic tissue, and the dominant negative proteins and were not detected. The 'b' and 'c' isoforms may be suppressed in active tissue allowing excessive growth seen in both BPH and prostate cancer. It is possible that manipulation of the expression of these splice variants could be performed to inhibit excessive growth.
Introduction
The polymorphic PSA gene has a G 7158 A variation within its regulatory sequence that affects one of two androgen response elements. This polymorphism has been reported to influence outcome but not susceptibility to breast and prostate cancer. Thus, the GG genotype was associated with good survival in breast cancer 1 
Many tumours overexpress an isoform of the glycolytic enzyme pyruvate kinase, type M2. It is released from tumour cells into the circulation and is quantitatively detectable with an upper limit of normal of 15 U/ml. The aim of the study was to measure M2-PK in prostatic disease. Methods A total of 127 men with prostatic disease had blood samples taken for M2-PK (EDTA plasma) and PSA (serum). M2-PK was measured using an ELISA and PSA using an automated enzymeimmunometric assay. Results Of the 60 patients attending for TRUSS biopsy, 40 patients had BPH and 20 had CaP. Median (IQR) M2-PK was 15.2 (11.9) U/ml in those found to have BPH and 20.8 (20.2) U/ml in those with CaP (P ¼ 0.04). Median PSA was 4.9 (6.4) mg/l in BPH and 12.2 (36.4) mg/l in CaP (P < 0.001). M2-PK had a sensitivity of 70% and a specificity of 51% for the detection of CaP. For PSA there was a sensitivity of 83% and a specificity of 42%. There was however no correlation between M2-PK and PSA (r s ¼ 0.16, P ¼ 0.06). Fifty-five patients had received hormonal or radiotherapy with median M2-PK 34.8 U/ml and PSA 3.85 mg/l. Twelve patients had hormonally relapsed disease with median M2-PK 41.7 U/ml and PSA 179 mg/l. Conclusion These results indicate that in ongoing prostatic malignancy there is increasing expression of M2-PK even in those who have received treatment. PSA, however, is reduced with treatment until becoming hormonally resistant. M2-PK may also help in identifying those patients with malignancy but a low PSA.
Her-2/neu is a receptor-type transmembrane protein, and is significantly elevated in the serum of breast cancer patients. It exhibits sequence homology with epidermal growth factor receptor, and its amplification in breast cancer is associated with poor prognosis and metastasis. Immuno-histochemical staining shows it to be overexpressed in prostate cancer, and its expression level is linked to poor prognosis. We wished to see if it might be detected in the serum of men with early prostate cancer. Methods Serum samples were taken on 104 men; 98 were undergoing a TRUSS biopsy for suspected CaP and six had hormonally resistant disease. Serum Her-2/neu determination was carried out by an immunoenzymetric assay.
Results
Of the men undergoing biopsy 39 were found to have BPH and 59 Ca prostate. The mean PSA for those with benign disease was 4.9 mg/ ml (6.4). For those with Ca Prostate it was 12.2 mg/ml (36.4), giving a sensitivity of 83% and specificity of 42%. The mean Her-2/neu for benign disease was 10.2 ng/ml (2.03), and for Ca prostate 9.6 ng/ml (2.04). For those with hormonal resistant disease the mean PSA was 276.1 mg/ml (range 48.6 -594). The Her-2/neu was 11.1 ng/ml (range 4.6 -15.6). Conclusions Unlike patients with breast cancer serum levels of Her-2/ neu were not found to be useful in differentiating between benign and malignant prostate disease. Nor does it seem to be elevated in a small number of patients with hormonally resistant disease.
Introduction
Advances in molecular technology and in particular its application to the field of cytogenetics, has recently provided an innovative tool to explore the complexity of those genetic events underlying carcinogenesis in prostate cancer. Multiplex (M-FISH) or 24 colour fluorescent in-situ hybridization has evolved from improvements in fluorescence technologies such that each of the 24 human chromosomes can be identified simultaneously in 24 discrete colours. As such chromosomal re-arrangements can be identified between all chromosomes imaged in a single metaphase spread and reflects a significant advance on conventional cytogenetic analysis. We have applied this emerging technology to a series of 10 prostate cell lines which range from the benign to the hyperplastic and subsequently to both androgen dependent and independent malignant disease. Method Cell lines were cultured in RPMI and 10% FCS and incubated at 37 C in 5% CO 2 . Metaphase spreads were obtained after treating with colcemid for 2 -4 h and incubating with hypotonic potassium chloride. Cells were fixed with methanol and acetic acid after spreading onto slides. M-FISH was performed in accordance with manufacturers guidelines and imaged with an Olympus Provis fluorescent camera. A minimum of 10 metaphase spreads were examined for each cell line with re-arrangements classified as clonal when detected in two or metaphase cells. Results Marked differences in the patterns of interstitial deletions and amplifications were noted between cell lines. With the transition from benign to malignant to androgenindependent disease came increasing evidence of genomic instability. A series of novel chromosomal rearrangements were identified which may prove of diagnostic utility. Hormone refractory cell lines exhibited a higher number of chromosonme rearrangements and supports previous analysis using comparative genomic hybridization. Conclusion Cytogenetic analysis of prostate cancer cell lines provides an indication as to the nature and sequence of somatic genetic changes which occur in the evolution of carcinogenesis and may prove to be of clinical utility in the management of patients at varying stages of disease progression. More importantly it offers the hope of identifying specific markers of progression of malignant disease from hormone sensitive to the androgenindependent disease state. The progression of carcinomas is associated with loss of epithelial morphology and a concomitant acquisition of a more mesenchymal phenotype, which in turn is thought to contribute to the invasive and/or metastatic behaviour of the malignant process. Changes in the expression of cadherins, 'cadherin switching', plays a critical role during embryogenesis particularly in morphogenetic processes. Loss of E-cadherin is reported to be associated with a poor prognosis, however so far only in cell lines evidence for upregulation of other cadherins was found, ie we have found evidence for cadherin switching in prostate cancer cell lines (upregulation of N-cadherin and cadherin-11, two mesenchymal cadherins, in cell lines that lack a functional E-cadherincatenin adhesion complex). We studied cadherin subtype expression immunohistochemically using N-cadherin and cadherin-11 specific monoclonal antibodies in human prostate cancer specimens. N-cadherin was not expressed in normal prostate tissue however, in prostatic cancer N-cadherin was found to be expressed in the poorly differentiated areas, which mainly show aberrant or negative E-cadherin-staining. Cadherin-11 is expressed in the stroma of all prostatic tumours, in the area where stromal and epithelial cells are. In addition, cadherin-11 is also expressed in a dotted pattern or at the membrane of the epithelial cells of high-grade cancers. In a number of metastatic lesions N-cadherin and cadherin-11 are expressed homogeneously. These data raise the possibility that cadherin switching plays an important role in prostate cancer metastasis. The main challenge now is to investigate how the cadherins interact with other adhesion and signalling mechanisms. It is well established that E-cadherin participates in multimolecular complexes, and is an integral part of the wnt/ wingles pathway. We, therefore, aimed at identifying cell adhesion molecules from other superfamilies that colocalize with E-cadherin. One candidate is ALCAM which is also implicated in homophilic cell adhesion and that is up-regulated in several cancer types, including melanoma and bladder cancer. In PC3 cells E-cadherin-mediated interactions are absent due to a homozygous deletion of alpha-catenin. We were able to restore E-cadherin junctional complexes by transfection of alphaN-catenin. Strikingly ALCAM concomitantly with E-cadherin relocated to the cell contacts. Further detailed analyses using multiparameter confocal laser scanning microscopy analysis showed that E-cadherin and ALCAM colocalized. In biochemical analyses of the complexes using co-immunoprecipitation, however, we were unable to find evidence for a direct molecular interaction of E-cadherin or alpha catenin with ALCAM. Hence, we hypothesized that another yet unknown protein can mediate the interaction between E-cadherin and ALCAM in the cortical cytoskeleton. One candiate came from a two hybrid screening using alpha-catenin as bait, namely TH9 encoding a putative 28 kDa MW protein.
Previously, co-immunoprecipitations with ALCAM antibodies identified a protein of 30 kDa, ie of similar molecular weight. TH9 partly colocalized with ALCAM and Ecadherin. Preliminary co-immunoprecipitation experiments did not provide conclusive evidence for a direct molecular link between TH9 and alpha catenin. The colocaliztion experiments, however, are striking and it is conceivable that the interactions between the proteins are only transient.
Thus, it appears that the well documented down regulation of E-cadherin is not only associated with upregulation other cadherins, but that also other adhesion molecules are directly or indirectly affected.
To date, more than 70 consistent chromosome rearrangements have been identified in human leukaemia and lymphoma, many of which have diagnostic, prognostic and patient management implications. However, in solid tumour, such as carcinoma of the prostate significantly less is known, in particular the cytogenetic events involved in its development and progression. In a recent study, we identified a reciprocal translocation between chromosomes 1 and 15 in the cell line, LNCaP, as well as rearrangement of 1p in two other prostate cancer cell lines. 1 Genes relevant to prostate cancer may be harboured within these rearrangements and it is hoped that, through FISH mapping studies and consequent molecular cloning, gene targets can be identified that may be diagnostic or prognostic in patients with prostate cancer. Methods To investigate the t(1;15) translocation more than 70 bacterial and phage artificial chromosome clones (bacs and pacs) were prepared for fluorescence in situ hybridization (FISH), and sequentially mapped to both normal chromosomes and those from the LNCaP cell line. Once a FISH probe was identified that spanned the breakpoint, probe fragments were produced within this FISH clone using long-range polymerase chain reaction (LR-PCR) and mapped to the LNCaP chromosomes to further refine the breakpoint. Results FISH mapping demonstrated that the clone RP11-32 spanned the breakpoint region of the t(1;15) in LNCaP. This clone is 180 kb in size and the region containing the breakpoint was further reduced to less than 115 kb using mapping data from above and below the RP11-32 clone. LR-PCR was used to further refine the breakpoint and gene homology database analysis revealed one 4 kb gene in this segment. Conclusions FISH mapping studies have localized the t(1;15) breakpoint to be within or near a gene of interest known to be involved in cancer development and progression. This gene contains five exons and is a polypeptide growth factor regulator known to influence cell migration, interaction, proliferation and differentiation, as well as angiogenesis and mutant p53 functional activity. Recently, it has been demonstrated that this gene was underexpressed in a small series of primary prostate tumours. Further molecular investigations are planned to elucidate the exact nature of this cytogenetic aberration and to investigate the frequency of this change in primary tumours.
Urologists have to decide whether aspirin should be stopped prior to transurethral resection of prostate (TURP), and need to be able to justify their decision should cardiovascular complications arise. We therefore investigated the management of aspirin by British Urologists in patients undergoing TURP. Methods A total of 444 British consultant urologists were sent questionnaires; 287 replies (65%) were received. Results A total of 178 out of 287 (62%) stop aspirin prior to TURP. On average aspirin is stopped 9.8 days (median 10; range 2 -42) prior to surgery and recommenced 8.8 days (median 7; range 1 -42) after surgery. Even in those that wish aspirin to be stopped, 60% will perform a TURP if the use of aspirin has inadvertently continued. In all, 109 out of 287 urologists (38%) do not stop aspirin prior to TURP. Some 58% of these believe that aspirin increases TURP blood loss, and 90% believe that the cardiovascular risks of stopping aspirin outweigh the urological benefits. Conclusions This study highlights a wide variation in practice with regard to aspirin. A randomised trial of aspirin vs placebo in TURP suggests that aspirin increases post-operative blood loss, but does not increase operative blood loss or transfusion requirements. The cardiovascular risks of stopping aspirin have not been determined. Formal multidisciplinary guidelines are required.
Human prostate specific transglutaminase: a highly specific differentiation linked prostatic marker H Rippon and NJ Maitland YCR Cancer Research Unit, Department of Biology, University of York YO10 5DD, UK Introduction Transglutaminases are a family of enzymes which catalyse the crosslinking of peptide-bound glutamine residues and primary amine groups to form protein -protein and protein -polyamine complexes. Prostatic transglutaminase (hTGp) has previously been shown to be a highly specific marker of normal prostate luminal epithelium. hTGp mRNA and protein have never been detected extraprostatically, in contrast to markers such as PSA and PSMA. 1, 2 We wished to further elucidate the apparently highly restricted expression pattern of hTGp by investigating endogenous hTGp expression in a range of commonly used prostate and non prostate cell lines. Methods RT-PCR was performed on total RNA extracted from prostate (LNCaP, PC-3, PNT1a, PNT2-C2, P4E6) and non-prostate (293-HEK, MCF7, MDA-MB-231, HeLa, HaCAT) cell lines, to detect the presence of hTGp mRNA. To induce hTGp expression in prostate cell lines, cells were incubated with the demethylation agent 5-aza-2 0 deoxycytidine or the histone deacetylase inhibitor trichostatin A for 4 days prior to RNA extraction. Results No endogenous hTGp expression was detected in any of the cell lines tested, and expression could only be induced in LNCaP cells by 5-aza-2 0 deoxycytidine. No other cell line responded to either drug treatment. Induction of hTGp in LNCaPs by 5-aza dC was abolished by the substitution of charcoal stripped media and could not be rescued by the addition of DHT. Conclusions hTGp displays a uniquely restricted expression pattern suggestive of a strong dependence on cellular differentiation. LNCaP cells were the only cell line in which endogenous hTGp expression could be induced, however the presence of an intact androgen response pathway does not appear to be the sole distinguishing factor. DHT alone could not restore hTGp induction when cells were incubated in steroid and growth-factor depleted medium. Most prostate cell lines display characteristics broadly synonymous with basal epithelium, whereas LNCaP cells have retained some of the differentiated functions of luminal secretory epithelia. This suggests that the highly specific expression pattern of hTGp arises through the assimilation of multiple signals on the hTGp promoter, the full complement of which is present only in fully differentiated, luminal prostate epithelium. 
Results
Of the 510 RRP patients, with a mean age of 61 years (range 45 -76) and a mean follow-up of 30 months (range 2 -89), 48 patients (9.4%) developed an anastomotic stricture. In these patients bladder neck contracture occurred within 3 months of surgery in 36 patients (75%), at 4 -12 months in nine men (18.7%) and beyond 12 months in three (6.2%) patients. In addition, nine men (18.7%) required more than one dilatation (usually two procedures) and five patients required intermittent clean selfcatheterization (ICSC) for a 2 -3 month period. All eventually voided well with a normal flow. Conclusion Stricture of the vesico-urethral anastomosis after bladderneck sparing RRP is not an infrequent complication and most patients are successfully managed with a single dilatation. A small number of cases required several dilatations or a period of ICSC. Eventually all patients were stabilized satisfactorily.
Introduction DISC-HSV is a replication incompetent herpes simplex virus that is a highly efficient vector for the transduction of genes in vivo and in vitro. Here, we examine the ability of DISC-HSV to infect a variety of human prostate cancer cell-lines (DU145, PC3, LNCaP) and induce expression of human cytokine/reporter genes. The effects of metabolic activity, proliferation rate and rate of cell death following viral infection on the production of virally encoded gene products is investigated. Methods Optimum conditions for viral infection were ascertained by dose escalation studies. Infection was confirmed by cellular staining for the beta-galactosidase reporter gene product, and by electron microscopy. The production of GMCSF by cells infected with DISC-HSV containing the GMCSF gene was measured using an ELISA. A colorimetric assay of NADP/NADPH was used to determine the metabolic activity of infected cells, and cell proliferation was determined by cell counting under light microscopy after trypan blue staining. Cell death was estimated by cell-cycle analysis of infected cells using flow cytometry with propidium iodide staining. The ability of DISC-HSV to infect solid tumours in vivo was assessed by electron microscopy of human prostate cancer xenografts in nude mice following direct intra-tumoural injection with DISC-HSV. Results Infection of DU145, PC3 and LNCaP cells with HSV-DISC was shown to be dose-dependent and the presence of intra cellular viral particles was confirmed by electron microscopy. Cells infected with HSV-DISC containing the granulocyte-macrophage colony stimulating factor (GMCSF) gene released high levels of GMCSF for at least 3 days following infection. The levels of GMCSF released by non-infected controls and cells infected with an irrelevant DISC-HSV virus were negligible. NADP/NADPH assay suggested that infected cells continued to be metabolically active for at least 3 days post infection, and no significant reduction in cell number was demonstrated.
Flow cytometry demonstrated significant changes in the cell cycle of infected cells, but without a major accumulation of the necrotic/late apoptotic fraction. Tumour xenografts injected with DISC-HSV stained positively for the beta-galactosidase reporter gene, with intracellular viral particle demonstrated on electron microscopy. Discussion In previous studies we have reported that established tumours could be rejected following intra-tumoural injection of DISC-HSV expressing GMCSF and this rejection was shown to be CD 8þ and CD 4þ T-cell dependent. Additional studies have shown HSV-DISC to be safe for intratumoural injections in humans and phase I clinical trials in melanoma patients are now underway. This study demonstrates the ability of DISC-HSV to infect prostate cancer cells and express significant levels of GMCSF over several days, and the reduction in GMCSF production after 3 days cannot be explained by apoptosis or necrosis, nor a reduction in metabolic activity. Furthermore the virus is able to infect solid prostate cancer tumours in vivo, and induce expression of virally encoded genes.
Conclusion
In summary, these data demonstrate that DISC-HSV is able to infect human prostate cancer cells and express consistent levels of GMCSF over several days. We suggest that prostate cancer could be an appropriate target for therapy using HSV-DISC containing GMCSF.
Introduction
A uro-oncology nurse specialist within Essex Rivers Healthcare Trust, (population 320 000), is conducting an NHS Modernization Agency Pilot Study, in line with the strategy of the New NHS Plan. Our aim is to test the practicality and safety of a nurse-led, protocol based, telephone follow-up service for patients with 'stable' prostate cancer using a PSA as the principle surrogate for an outpatient attendance. Over the last 12 months, 80 patients fulfilling the entry criteria defining 'stable' prostate cancer on watchful waiting, after hormonal manipulation or after radical treatment (surgery/DXT) have been recruited.
Patients and methods
Telephone follow-up is conducted using a protocol detailing IPSS performance staus, pain assessment, serum creatinine and PSA assessment. Any break in protocol triggers an outpatient appointment.
Results
Patients have provided evidence of their satisfaction with the professional, patient-centred, continuity of care this service now provides and the majority prefer the telephone follow-up. In addition the service is releasing capacity within the consultant outpatient clinic, for more appropriate cases. No serious adverse events have occurred. Nurse-led protocol-based prescribing and follow-up for uncomplicated bladder outflow obstruction is now being introduced.
Conclusions
The pilot study has so far demonstrated a high level of user satisfaction, achieving its aim of providing a safe, more patient-centred service. The uro-oncology nurse has more time to reassure the patient and relatives and give timely advice and information as and when required. The patient also has the opportunity to contact the nurse whenever they need, which they find extremely valuable. We estimate on progress to date that our clinical activity will equate to 18 h of outpatient clinic time.
To investigate the relationship between the volume of high grade prostatic intraepithelial neoplasia (HGPIN) and invasive cancer S Sandhu, T Walker, M Jarmulowicz, D St George and A Kaisary The Royal Free Hospital, London, UK Introduction Prostatic intraepithelial neoplasia (PIN) can be divided into high-grade (PIN 3) and low-grade (PIN 1 þ 2) . The importance of low-grade PIN is not clear. It has been proposed that high-grade prostatic intraepithelial neoplasia progresses to invasive prostate cancer. This has been supported by a study demonstrating an inverse relationship between the volume of prostate cancer and the volume of prostatic intraepithelial (high and low). 1 It was the aim of this study to determine if the volume of high-grade PIN correlates with the volume of invasive cancer.
Method
Step sections of 76 consecutive radical prostatectomy specimens were examined prospectively. The total volume of the gland, the volume of cancer, benign tissue and HGPIN was calculated by marking regions of interest and using proprietary computerized planimetry software.
Results
The mean calculated total volume of the gland ¼ 50.42 ml (range 19.3 -155.5 ml), cancer volume ¼ 2.4 ml (range 0.01 -15.2 ml), and benign volume ¼ 47.47 (range 13.2 -153.4 ml). The calculated volume of the gland correlated with the weight of the gland (P < 0.0005, r ¼ 0.9353). There was a weak inverse correlation with volume of HGPIN and the volume of invasive cancer (r ¼ 70.203, P ¼ 0. 08), but there was a significant correlation between the volume of the gland and the volume of high grade PIN(r ¼ 0.3, P ¼ 0. 04).
Conclusions
In this study we have demonstrated a correlation between the volume of high grade PIN and the total volume of the gland. In view of high grade PIN being a putative precursor of invasive cancer this finding needs further investigation.
Introduction
In the majority of prostate cancer there are no inherited defects affecting high-penetrance susceptibility genes and malignancy arises as a result of a series of acquired somatic genetic changes affecting genes on several chromosomes. It is estimated that between five and 10 genetic alterations accumulate into a cell before it becomes fully transformed with additional losses and gains occurring before malignant transformation. The pattern and sequence of these somatic change remains obscure. We have applied recent microarray technology to the elucidation of patterns of loss and gain and compared those changes across a series of prostate cell lines ranging from benign to hyperplastic to androgen sensitive and independent disease. Method A series of 10 prostate cell lines were established and DNA extracted as per manufacturers guidelines (Qiagen). Reference and test DNA was labelled with fluorochromes by a random primer labelling reaction. DNA was hybridized to the Genocensor Array 300 and allowed to incubate for 62 -66 hours at 37 C. Following a series formamide and standard SSC washes the arrays were imaged and processed after conter-staining with DAPI. Results Novel patterns of gene amplification and deletion were highlighted by the GenoSensor Array 300 system and were reflected by interphase FISH analysis of specific markers such as the amplification of c-myc in the PC-3 cell line. With the progression of malignant disease from androgen sensitive to independent disease came the increased frequency of gene deletions and amplifications. Conclusion Such patterns of gene loss and gain may prove to be of clinical utility in monitoring disease progression and may prove of use in directing both conventional and innovative (anti-sense) treatment protocols.
How reliable are preoperative prostate biopsies? S Sandhu, T Walker, M Jarmulowicz, D St George and A Kaisary The Royal Free Hospital, London, UK Introduction TRUS-guided systematic sextant biopsies are the standard method to obtain tissue from the prostate. In this study we attempted to correlate the information obtained from preoperative sextant biopsies with radical prostatectomy specimens.
Material and methods
The results from pre-operative 18 G sextant biopsies were compared with histopathological map of 120 radical prostate specimens (T1 1 -2 ¼ 89, T 3 -4 ¼ 31). Each prostate map was divided into the six regions sampled by the TRUS guided biopsies. Each biopsy was sent for assessment individually. For each region the presence or absence of tumour in the biopsy was compared with the findings of the radical prostate specimen. Results The prostate Gleason score was predicted precisely in 58 cases (47%). The prostate or biopsy Gleason score did not correlate with tumor volume. The number of positive biopsies correlated with tumour volume (r ¼ 0.459, P < 0.0005) and stage. In particular the presence of tumour in the apical biopsies was predictive of higher stage disease (P< 0.05). The sensitivity, specificity, positive predictive and negative predictive value of the biopsies was calculated for each of the six regions. The range for the sensitivity was 69.2 -44.8% (mean 58.1%), for specificity it was 90.9 -53.8% (mean 75.8%), for positive predictive it was 97.5 -33.3% (mean 72.4 %), and for negative predictive value it was 81.4 -17.2% (mean 51.2%). Conclusion TRUS-guided sextant biopsies can aid in predicting tumour Gleason score, tumour volume, and stage, however their value in determining the exact tumour location is limited. Therefore the extent of operative resection should not be based upon the information obtained from preoperative biopsies. 
Introduction
Evidence demonstrating that height is related to prostate cancer risk has been suggested through epidemiological studies. 1 -3 A stronger association has been found with advanced prostate cancer rather than the localized form of the disease. 4, 5 It has been hypothesized that the mechanism is via androgen and/or insulin-like growth factor-1 (IGF-1) acting during puberty. 6 We have investigated the possible role of growth-related endocrine mechanisms in familial prostate and sporadic cancer. Objectives To investigate the effect of adult height on the risk of developing both localized and advanced prostate cancer by using benign prostatic hyperplasia (BPH) or 'latent' cancer patients as 'controls'. To examine height in cases with a significant family history. Methods A case -control study comprising 428 malignant cases, 164 latent cases and 559 BPH cases from Nottingham City Hospital and Sheffield Royal Hallmashire Hospital. Data on height and possible confounding factors were obtained by self-administered questionnaire. Case and control definitions Advanced cases were patients aged 80 with Gleason Score Grade ! 7 or PSA (plasma specific antigen) ! 20 nmol/l or with evidence of metastatic disease on plain X-ray or bone scan or had been treated with hormonal manipulation. Latent cases were patients with Gleason score grade 6 and no evidence of metastatic disease or with normal PSA level 4 nmol/l or with less than 5% of TURP (transurethral resection of the prostate) specimen. Benign prostatic hyperplasia cases were patients who were diagnosed as having benign prostatic hyperplasia only.
Results

Advanced cases and BPH controls
Risk increased with increasing height. Among the highest category (> 190 cm), risk is increased to 2.83 (95% CI 0.87 -9.15) compared to baseline (ht < 170 cm). There is a statistically significant gradient of risk with increasing height (P for trend ¼ 0.02). Within the familial cases, specifically, the risks were particularly high. Advanced cases and latent controls Height distribution was more similar within these two groups. A non-significant increased risk was found with height > 190 cm with an odds ratio of 1.9 (95% CI 0.39 -9.56). There was no trend with increased height and prostate cancer risk (P for trend ¼ 0.29). Within familial cases the risk did increase but was not as pronounced as when BPH controls were used. Conclusion Height was seen to show a significant association with prostate cancer compared to BPH controls. The risks were particularly high in cases with a familial history of prostate cancer, suggesting possible targets for searching for the genetic factors involved in familial risk. Risks were lower when latent cases were used as the control group.
Introduction
Men who do not die of prostate cancer may still suffer appreciably from the condition, but this morbidity is difficult to quantify. One way to investigate it is to evaluate the use of supportive services by patients. We therefore assessed the use of palliateive services by prostate cancer patients in relation to other cancer groups to identify the relative morbidity suffered by patients with prostate cancer.
Patients and methods
A retrospective analysis of palliative care referral, inpatient and outpatient activity was undertaken in respect to patients groups with nine common cancers. In addition, a prospective study of a cohort of men diagnosed with prostate cancer in 1993 was followed for 5 years. The records of those that died during this period were analysed and the palliative and hospice care services confirmed the type and duration of hospice care they had received. Results In all, 25.4% of the 118 men who died from or with prostate cancer used hospice services before death; 23% used the outpatients services, for an average of 68.8 days whilst 7% used the inpatient services, for an average of 8.25 days. Prostate cancer formed 9.5% of palliative care referrals per year and represents the third largest group of referrals. The average age of referral for prostate cancer was 72 yrs (s.d 51 -87) and the average survival time after referral was 3.8 months. After reviewing inpatient admissions and length of stay, prostate cancer patients were identified to have the third highest total use of inpatient services at 12%. Conclusion Prostate cancer patients suffer significant morbidity as a result of the disease. This leads to a significant use of palliative care services and should be included in comparisons assessing and planning health care strategies for prostate cancer.
Alternative medications for BPH on the Internet -is there any evidence for their usage? J-P Meyer and DA Gillatt Bristol Urological Institute, Southmead Hospital, Bristol, UK
Introduction
The number of people using alternative medications for the treatment of BPH has increased in recent years. One of the main reasons for this is the increasing public awareness of these previously unheard of products, through the expansion of health food shops but particularly through the escalating usage of the Internet by patients. Increasingly, patients are using this route to look for alternatives to 'conventional' treatments for BPH. We sought to do an Internet search for alternative medications for BPH, to see what was available for patients, and to assess the evidence to support their usage.
Materials and methods
Using the words 'alternative medications for BPH' an Internet search was performed. Each of the first 75 sites identified by this search were visited. From these sites information was recorded concerning whether general information was being offered, or whether a product, or products were being marketed. Having identified these products a Medline search was conducted to see if there was any evidence available to support their usage by today's urological patient.
Results
The Internet search revealed in excess of 1000 sites. Of the first 75 sites visited; 24 (32%) sites offered general information on alternative medications and 51 (68%) were marketing a product or products. Products advertised included; saw palmetto (Serona repens), African plum (Pygeum africaneum), South African star grass (Hypoxis rooperi), and pumpkin seeds (Cucurbita pepo). Reviewing the amounts of ingredients contained within these products it was seen that these varied between manufacturers.
Using the names of these alternative medications, a Medline search was conducted in order to assess if and what evidence was available to justify their usage. This search revealed limited evidence to support their efficacy, and many of the quoted studies used supraphysiologic dosages, thus leaving the significance of some of the studies open to debate. In addition to this, in several studies only small numbers of patients were used, often without a placebo group, thus making the reported improvements in symptoms, potentially only the result of a placebo effect. Conclusions From the Internet search it was seen that several alternative medications are available for the treatment of BPH. Despite the increased availability and usage of these products the evidence to support their usage is often quite limited. In order to support usage of these products, randomized placebo -controlled trials are warranted, only then can they be confidently and safely be recommended to patients.
Introduction
Prostate brachytherapy is increasingly available as treatment for early prostate cancer in the UK. We report results from our first 145 consecutive patients including early complications and PSA outcome and our ability to predict these pre-implant.
Patients and methods
Prospective patient assessment comprising uroflowmetry, IPSS questionnaires, physical examination and transrectal ultrasound was performed. seventy-nine patients received full urodynamic assessment. IPSS scores and PSA were recorded at 3-monthly intervals following treatment and events including acute urinary retention (AUR) and rectal symptoms recorded prospectively. Mean follow up was 13 months (range 1 -34). Result No patients were incontinent following treatment. Temporary deterioration in IPSS score occurred in 96% of patients. Peak symptoms occurred at 6 weeks and a statistically significant deterioration in IPSS persisted for 9 months but continued to improve throughout followup. Acute urinary retention affected 10% of patients with a further 20% using clean intermittent self-catheterization for symptoms. Two patients required surgery for bladder outflow obstruction. Urodynamically unobstructed patients did not require catheterisation. By 2 years postimplant mean IPSS scores were improved compared with preimplant scores. Eight patients had mild, transient proctitis. Mean PSA at 1 and 2 years was 0.7 and 0.5 ng/ml, respectively, and was not significantly different amongst patients treated with or without antiandrogens. Local recurrence occurred in one patient. Conclusion Urodynamic evidence of obstruction seems helpful in predicting risk of AUR. Prostate brachytherapy may be safely delivered to a UK population with excellent early PSA-progression-free survival and symptomatic outcome.
Introduction
The management of urinary retention ranges between conservative and surgical options. Our practice of immediate TURP when indicated aims to avoid the morbidity of long catheterization. In addition to clinical outcome, efficiency of resource use such as bed utilization is an important quality consideration in formulating care pathways. We present a critical review of our approach. Patients and methods A total of 125 male patients admitted with urinary retention were entered into a prospective audit over a 12-month period, using a predetermined protocol. The demographic, hospitalization and outcome data of those who underwent immediate TURP at the earliest available operating list were compared with 37 elective TURP patients. Results Eighty-one patients had TURP of whom 50 (61.7%) mean age 70.8 AE 8.2 proceeded to immediate surgery. Their age was similar to elective patients (P ¼ 0.5). Hospitalization was longer than elective patients (P < 0.001) and this was mainly due to pre-operative admission. As would be expected, significantly more elective patients 95% vs 76% voided following catheter removal (P < 0.02). There was no significant difference in the age of those who voided and those that failed (P < 0.1). However, the residual urine at catheterization was larger in those who failed to void (P < 0.01) while the prostate glands were smaller (P < 0.005). The surgical complications were comparable to published figures. 1 Conclusion Immediate surgery is safe but patients stay longer. A period of catheterization seems unavoidable in the patients with large residual urine. These patients are therefore probably more effectively managed by a period of catheterization at home prior to elective surgery.
The symptom severity of men presenting in primary care with LUTS is similar to that of an aged-matched population who have not sought medical treatment. Why some men seek help and others don't remains illusive. The extent to which a fear of prostate cancer drives healthseeking behaviour is not known. At least four highquality studies have shown that men with LUTS are at no greater risk of prostate cancer than asymptomatic men of the same age.
Materials and methods
Qualitative semi-structured interviews were conducted with men who attended outpatients with uncomplicated LUTS (that which causes no serious health threat). The aim was to explore their experiences, opinions and beliefs about prostate cancer. Interviews were audiotaped, transcribed and analysed using grounded theory methods. Results Thirty men were interviewed (15 Teaching Hospital and 15 District General Hospital). Mean age 71 (54 -80) years. twenty-two of 30 (73%) expressed fears about prostate cancer at the time of presentation. This was independent of race and social class and inversely proportional to age P < 0.05 (older men were less worried). Half of the men had personal experience of friends or relatives with prostate cancer. These men stated their symptoms were unchanged when reassured on this matter, but they were less bothersome and easier to cope with.
Conclusion
The perceived risk of prostate cancer greatly exceeds the actual risk. Management of men with LUTS will be suboptimal unless issues relating to prostate cancer are explicitly addressed. How best to do this is part of an on-going research study.
Can peri-prostatic local anaesthetic reduce pain during TRUS biopsy of the prostate -prospective, randomized, placebo-controlled trial T Nambirajan, S Woolsey, V Mahendra, M Shaffl, PF Keane and TH Lynch Belfast City Hospital, Belfast, UK Objective Trans-rectal ultrasound (TRUS)-guided biopsy of the prostate has become a routine outpatient procedure in urological practice. Although tolerated by many, there is significant discomfort for some. We performed prospective, randomized study of the role of peri-prostatic local anaesthesia to reduce the discomfort during TRUS biopsy. Materials and methods Fifty men (mean age 64.35, range 47 -74) undergoing TRUS biopsy for elevated PSA or abnormal digital rectal examination were recruited after obtaining informed consent. Ethical approval was obtained. The patients were randomized into local anaesthetic (LA) or placebo group by sealed envelope method. An 18G needle was passed through the biopsy channel of the TRUS probe and 5 ml of 1% lignocaine was infiltrated on either side of the prostate, 2.5 ml each in base (angle between seminal vesicle and prostate) and apex of the prostate. In the placebo group the needle was passed without injection of any material. Six to 10 biopsy cores were taken, the majority being 10. Patients were asked to fill in the expected pain score prior to the procedure to assess the element of anxiety involved. They also completed a visual analogue score after the biopsy. Statistical analysis was by independent sample t-test and non-parametric Mann -Whitney U-test.
Results
The age was comparable in both groups. The expected pain score was comparable (4.86 AE 1.86 in LA, 4.64 AE 1.38 in placebo). In the LA group, the mean pain score was 3.1 AE 2.16 and in placebo group 6.6 AE 2.5. This difference is statistically significant. Since the expected pain sore was comparable in both groups, the level of anxiety did not account for the observed difference. When patients were asked whether they would undergo the procedure again in the same way, 100% of the LA group and only 64% of the placebo group responded 'yes'. This difference is statistically significant (P ¼ 0.002 using Fisher's test). Conclusion Peri-prostatic local anaesthetic with 1% lignocaine reduces discomfort significantly during TRUS biopsy and we feel it should be used routinely.
Avoid cruising on your flowmeter! SK Addla and PP Irwin Leighton Hospital, Crewe Introduction Uroflowmetry is a fundamental investigative tool in urology. We assessed the reproducibility of three flowmeters in our department using fluid delivery at different rates.
Materials and methods
Three Uroflowmeters (spinning disc) were tested at flow rates increasing from 10 ml/s to 25 ml/s. Water was delivered through a motorized tube holder via a FR4500 series Acrylic block delivery system. Flow was aimed at (1) directly onto the spinning disc, (2) base of the funnel, (3) periphery of the funnel, and finally (4) in a wavy (cruising) motion from periphery to centre of the disc. Ten measurements of Q max and mean flow rates were recorded at each position. Results There was no significant difference between flow rate measurements when flow was aimed at a single point in the funnel, whether at the base, the periphery or directly onto the spinning disc itself. However, a significant difference in Q max (P < 0.0001) was observed between the measurements obtained from the spinning disc itself and those obtained by the wavy motion. Mean flow rates however were almost identical. The differences in Q max were:
1.6 ml/s (1.5 -1.8) at 10 ml/s; 2.2 ml/s (2.1 -2.4) at 15 ml/s; 3.3 ml/s (3.1 -3.7) at 20 ml/s; 3.6 ml/s (3.3 -3.8) at 25 ml/s. Conclusions Artificially high Q max measurements were obtained by a cruising flow delivery due to delayed return of fluid to the spinning disc from the periphery of the funnel. These findings emphasize the importance of integrating the Q max with the flow pattern in interpretation of Uroflowmetry. Where possible, patients should be cautioned against cruising on the flowmeter! Casodex (bicalutamide) vs cyproterone acetate in the prevention of tumour flare in advanced prostate cancer treated with GnRH analogue M Sugiono, M Winkler, A Okeke and DA Gillatt Bristol Urological Institute, Southmead Hospital, UK Introduction Administration of GnRH analogue in advanced prostatic carcinoma can cause disease flare in 4 -33% of cases. 1 Cyproterone acetate (CPA) is currently the most widely used antiandrogen to prevent this, although its adverse effects may limit its use. Casodex is well tolerated but peripherally selective and lacks progestational activity. 2 We conducted a pilot study to evaluate its efficacy in preventing disease flare by serial measurements of biochemical and clinical parameters. Patients and methods Twenty-two men were randomized 1:1 to casodex (50 mg daily) or CPA (100 mg 3x daily) five days prior to a 3.6 mg dose of zoladex (goserelin acetate) and continued for 21 days thereafter. Serum PSA, LH (luteinizing hormone), FSH and testosterone were obtained before treatment and on days 6, 8, 10, 16, 21 and 28. At each visit, urinary symptoms were assessed using the IPSS questionnaire and skeletal pain measured with a visual analogue pain scale. Results Both groups were of similar age and stage. The continuous downward trend of median percentage change in PSA from baseline was almost identical in the two groups and there was no significant difference in the median number of days (15 vs 12.5) before the PSA decreased by more than 75%. All patients in the casodex arm had an increase in LH/FSH compared to 5/11 (45.4%) receiving CPA (P < 0.01). As a result, the casodex group all showed a testosterone peak whereas only 3/11 (27.3%) on CPA did (P < 0.001). Three patients on casodex had skeletal metastases and one experienced a worsening of pain in the first week following zoladex administration, which resolved on day 16. Four receiving CPA had bony metastases and one developed more pain on day 16. None of the patients in the casodex group complained of a deterioration in urinary symptoms whilst one on CPA had a worse IPSS in the second week. Conclusion Despite the rise in testosterone and LH/FSH, casodex is able to suppress the initial PSA surge as effectively as cyproterone acetate. Furthermore, it appears to be equally good at preventing clinical flare and therefore provides a useful alternative when commencing GnRH analogue therapy.
Introduction
The development of a rising PSA in patients after radical prostatectomy may originate from local recurrence for which radiotherapy is given with curative intent, and/or distant metastases for which systemic treatment is required. Ultrasound-guided trans-rectal biopsies of the vesico-urethral anastomosis may be used to seek evidence of local recurrence as a cause of a rising PSA. We reviewed the value in clinical management of this invasive procedure in our practice.
Patients and methods
The case histories of 12 post-prostatectomy patients with either a rising PSA or abnormal DRE and negative bone scans, who had undergone anastomotic biopsies, were reviewed.
Results
The mean PSA at biopsy was 1.2 ng/ml (range 0.1 -6.2). Adenocarcinoma was reported in four patients, residual benign glands in two and prostatic tissue was not identified in six cases. Where cancer was diagnosed, all patients received immediate salvage external beam radiotherapy. Two patients with negative biopsies also received immediate radiotherapy due to clinical or radiological suspicion. The remaining six underwent watchful-waiting and five of these subsequently received salvage radiotherapy as their PSA levels continued to rise. One patient has had a stable PSA on surveillance alone (24 months). Of the 10 patients who proceeded to radiotherapy for presumed local recurrence, only four had had positive biopsies. No biopsy complications were recorded.
Conclusions
This small series has demonstrated that positive biopsies may assist in management, but negative biopsies cannot exclude local recurrence. In the majority of cases biopsy did not assist diagnosis and in fact in 42% (5) presumed false-negative biopsies delayed treatment. While anastomotic biopsies may be useful in certain patients, for most they are not warranted.
Entonox inhalation and tolerance of transrectal ultrasound guided (TRUS) prostate biopsy -a double-blind randomized controlled study J Masood, N Shah, T Lane, H Andrews, P Simpson and JM Barua Department of Urology, Harold Wood Hospital, Romford, Essex, UK Purpose A randomized placebo-controlled double-blind trial to evaluate the effectiveness of Entonox (50% nitrous oxide and oxygen) as analgesia during TRUS-guided prostate biopsy.
Materials and methods
Patients referred for TRUS-guided prostate biopsy for the first time as an outpatient procedure were recruited subject to exclusion criteria and randomized to breathe either entonox or air via similar breath activated devices. At the end of the procedure, patients completed a visual pain analogue scale. Patients who declined the study also completed the visual analogue pain scale to assess the placebo effect of receiving gas through a mask. Results A total of 110 patients were studied. Statistical analysis using a one-way ANOVA test showed a highly significant difference in pain perception between the three groups: F (2,107) ¼ 73.348; P < 0.001. This significant reduction in pain was between the Entonox group and air, and Entonox group and placebo. There was no significant difference between the air and placebo groups. Seven of 51 patients receiving Entonox complained of feeling drowsy during the procedure, which resolved upon completion of the procedure. Forty-nine patients in this group would be happy to undergo this procedure again if needed. Two of 45 patients in the group receiving air had their procedure abandoned due to pain. Another 19 preferred more analgesia and two would prefer a general anaesthetic if the procedure was to be repeated.
Conclusion
We have shown that Entonox is a safe, fast acting and effective form of analgesia for the pain of prostatic biopsy and believe it should be the analgesia of choice in this procedure.
A radiological diagnosis of chronic prostatitis T Lane, J Coucher, V Meganathan, M Gleeson, E Rogers and C Allen The Central Middlesex Hospital, Park Royal, London, UK
Introduction
To assess the role of dynamic MRI (dMRI) in the diagnosis of chronic prostatitis Methods Twenty patients with chronic prostatitis underwent Stamey localization studies and completed an NIH chronic prostatitis symptom score. All patients (and 10 normal controls) underwent MRI. Following the intravenous administration of gadolinium, gradient echo MR images were obtained using T 1 weighted 5 mm sections at 30 s intervals over a period of 7 min. Enhancement patterns at a number of regions of interest were recorded and plotted against time. Results Uniform prostatic enhancement was noted in normal controls. By contrast characteristic and preferential patterns of enhancement were noted in the transition zone (TZ) and peri-prostatic venous plexus (PVP) in the symptomatic patient with chronic prostatitis. Time signal intensity parameters (at specified regions of interest) provide 'dynamic' curves which vary with symptom scoresrapid enhancement patterns being correlated with higher symptom scores. Conclusion Contrast-enhanced dMRI reveals characteristic patterns of prostatic enhancement in chronic prostatitis and may be of diagnostic utility. In addition time-signal intensity curves may provide an indication of underlying disease activity and could be used as a tool to monitor the response to therapeutic interventions.
What is the quality of life for men without a prostate? K Thomas, SRJ Bott, D Besarani and RS Kirby Institute of Urology and Nephrology, London, UK; St George's Hospital, London, UK Introduction Radical retropubic prostatectomy (RRP) is commonly performed for the treatment of localized prostate cancer. Patients are routinely counselled regarding the risk of physical complications (eg erectile dysfunction and urinary incontinence). This study, however, assesses the impact of RRP on the patient's health related quality of life (HRQoL). Methods A self-completion questionnaire incorporating elements of the SF 36, IIEF and ICS-male questionnaires was sent to all patients who had undergone a RRP by one surgeon. Responses for the HRQoL domains; general, mental, emotional, physical, vitality social and sexual health are reported. Results A 77% response rate was achieved (322/420 patients). The mean age was 61 years (range 45 -76) with a mean follow-up of 30 months (range 2 -89 months). The majority of patients (91%) reported that their general health was better or the same following the RRP. No significant impact on either mental or emotional health was found. Vitality scores were high for > 75% of patients and physical activity was not limited, except vigorous activity where one third of patients reported some limitation. Eighty-eight per cent of patients reported minimal interference with social activities. Libido decreased after RRP for all patients (chi-square P < 0.001), however, when only patients with erections were analysed there was no statistically significant difference (chi-square P > 0.05). Conclusion RRP does not appear to have a significant impact on most aspects of HRQoL with the exception of sexual health for men who become impotent after surgery. These findings may be useful when counselling patients preoperatively.
Chronic prostatitis R Batstone
Addenbrooke's Hospital, Cambridge, UK Chronic abacterial prostatitis and prostatodynia (now referred to as chronic pelvic pain syndrome (CPPS) types IIIa and IIIb respectively, in the 1995 NIH classification) 1 are poorly understood conditions. They are surprisingly common and account for approximately 8% of visits to Urologists in the United States. 2 It has been documented that the impairment to quality of life from chronic prostatitis compares with that due to myocardial infarction, angina and Crohn's disease. 3 The aetiology is not known, and may be multi-factorial. However, there is an increasing body of evidence from animal models 4 and human studies 5 which support an autoimmune cause. Until the aetiology is fully characterized the diagnosis and treatment of this condition will remain unsatisfactory. The current sub-classification of types IIIa and IIIb prostatitis on the basis of white blood cells in the expressed prostatic secretion or on the post prostatic massage urine specimen is not ideal. This classification is arbitrary; dependant on obtaining EPS, the type of technique used to count WBCs, 6 and does not necessarily correlate with the finding of inflammation on prostatic biopsy. 7 The recent development of a validated symptom score for this condition (the NIH-Chronic Prostatitis Symptom Index, NIH-CPSI) will revolutionize CPPS. 8 and is an integral part of the patient's assessment and treatment monitoring. The NIH-CPSI has already allowed a large multi-centre randomized controlled trial, the North American Rofecoxib study. 9 Until similar studies have been completed, treatments for this condition will remain empirical. A recent review of the diagnosis and treatment of chronic abacterial prostatitis concluded that there is a paucity of diagnostic tests and that the current use of antibiotics and alpha-blockers in chronic prostatitis is not justified on the basis of available evidence. 10 This review highlighted the need for further RCTs.
